CVM (CEL-SCI) Short-Term Debt : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Short-Term Debt?

CEL-SCI's Short-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.

CEL-SCI Short-Term Debt Historical Data

The historical data trend for CEL-SCI's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Short-Term Debt Chart

CEL-SCI Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Short-Term Debt

Get a 7-Day Free Trial

CEL-SCI Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

CEL-SCI Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CEL-SCI Short-Term Debt Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

LSRM:Germany LSRM:Germany

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Executives

Geert R Kersten	director, officer: Chief Executive Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep	officer: Sr. Vice President, Operations	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Robert Eugene Watson	director	245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano	officer: Senior Vice President	8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Bruno Jean-marie Baillavoine	director	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor	officer: Chief Scientific Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman	officer: Sr. Vice President, Research	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Clara Maximilian De	director, officer: President
C Richard Kinsolving	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182